Quincy Marlin
Medical · Hueytown, ALNPI 1083207666
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 26.9% of the total.
Across 147 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$671
- GSK$490
- AbbVie$404
- Lilly USA, LLC$142
- Amgen$125
- Boehringer Ingelheim$107
- plus $552 from 10 others
What the payments were for
- Food & beverage$2,492100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $671 |
| GSK | 27 | $490 |
| AbbVie | 25 | $404 |
| Lilly USA, LLC | 9 | $142 |
| Amgen | 6 | $125 |
| Boehringer Ingelheim | 8 | $107 |
| Merck | 6 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Mylan Specialty L.p. | 4 | $67 |
| Pfizer | 4 | $64 |
| AstraZeneca | 4 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $49 |
| Exact Sciences | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $27 |
| Dexcom, Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $23 |
How this compares
$2,492 in reported general payments places this provider in the 75th percentile of 175 medical providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $14,995 |
| XareltoRivaroxaban | 20 | $13,256 |
| JardianceEmpagliflozin | 12 | $13,065 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,104 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,194 |
| Rosuvastatin Calcium | 38 | $1,106 |
| Atorvastatin Calcium | 79 | $992 |
| Metoprolol Succinate | 47 | $828 |
| Levothyroxine Sodium | 31 | $518 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $513 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $495 |
| Amlodipine Besylate | 51 | $430 |
| Celecoxib | 21 | $419 |
| Pravastatin Sodium | 24 | $404 |
| Pantoprazole Sodium | 49 | $394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $14,99520 claims |
| Boehringer IngelheimJardiance | $107 | $13,06512 claims |
| GSKTrelegy Ellipta | $490 | $10,10414 claims |
| AbbVieSynthroid | $404 | $27412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 175 medical providers in Alabama.
Other medical in Hueytown
- Lindsey MangumFlorence$44K
- Jaime DunnBirmingham$16K
- Stacy RichersonMobile$12K
- Susannah CashAuburn$11K
- Deana PorterAuburn$9K
- Rachel ThompsonFairhope$9K
- Shelley WinzelerHomewood$8K
- Reiga EvansHuntsville$8K
- Lillian ShafferCullman$8K
- Lauren TidwellHuntsville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.